PMID- 11466692
OWN - NLM
STAT- MEDLINE
DCOM- 20010809
LR  - 20201215
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 92
IP  - 2
DP  - 2001 Jul 15
TI  - Soluble human leukocyte antigen--G serum level is elevated in melanoma patients 
      and is further increased by interferon-alpha immunotherapy.
PG  - 369-76
AB  - BACKGROUND: The nonclassic human major histocompatibility complex class I 
      antigens human leukocyte antigen (HLA)--G are proposed to protect tumor cells 
      from natural killer cell lysis. In the current study, the authors measured 
      soluble HLA-G molecules (sHLA-G) in serum from patients with malignant melanoma. 
      METHODS: Soluble HLA-G was determined in serum samples of 190 melanoma patients 
      with various stages of disease, with or without current therapy including 
      interferon (IFN)-alpha and different cytostatics in comparison to 126 healthy 
      controls by using a two-step enzyme-linked immunoadsorbent assay. RESULTS: Serum 
      sHLA-G was significantly (P < 0.0005) elevated in melanoma patients (mean +/- 
      standard error of the mean [SEM] = 41.95 +/- 2.15 ng/mL) compared with healthy 
      controls (mean +/- SEM = 22.92 +/- 1.51 ng/mL). Univariate analysis revealed a 
      correlation of sHLA-G serum level with advanced stages of disease (P < 0.001) and 
      tumor load (P < 0.05). Patients undergoing immunotherapy with IFN-alpha (n = 31) 
      showed an increased serum sHLA-G (mean +/- SEM = 62.05 +/- 7.58 ng/mL; P < 
      0.0005), whereas other treatment regimens (n = 24) did not influence sHLA-G serum 
      concentrations. Multivariate analysis revealed treatment with IFN-alpha as the 
      only impact factor for elevated serum sHLA-G, lacking any correlation with stage 
      of disease or tumor burden. Furthermore, IFN-alpha was found to upregulate HLA-G 
      cell surface expression on circulating monocytes. sHLA-G serum level was not 
      associated with recurrence free or overall survival. CONCLUSIONS: This study 
      shows increased sHLA-G serum concentrations in melanoma patients and additional 
      enhancement upon treatment with IFN-alpha. The level of serum sHLA-G, however, 
      had no negative impact on patients' prognosis.
CI  - Copyright 2001 American Cancer Society.
FAU - Ugurel, S
AU  - Ugurel S
AD  - Department of Dermatology, The Saarland University Hospital, Homburg/Saar, 
      Germany.
FAU - Rebmann, V
AU  - Rebmann V
FAU - Ferrone, S
AU  - Ferrone S
FAU - Tilgen, W
AU  - Tilgen W
FAU - Grosse-Wilde, H
AU  - Grosse-Wilde H
FAU - Reinhold, U
AU  - Reinhold U
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-G Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Interferon-alpha)
SB  - IM
MH  - Antibodies, Monoclonal
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Biomarkers/*analysis
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Flow Cytometry
MH  - HLA Antigens/*analysis/biosynthesis
MH  - HLA-G Antigens
MH  - Histocompatibility Antigens Class I/*analysis/biosynthesis
MH  - Humans
MH  - Interferon-alpha/*pharmacology/therapeutic use
MH  - Male
MH  - Melanoma/drug therapy/*immunology/pathology
MH  - Middle Aged
MH  - Prognosis
MH  - Prospective Studies
MH  - Skin Neoplasms/drug therapy/*immunology/pathology
EDAT- 2001/07/24 10:00
MHDA- 2001/08/10 10:01
CRDT- 2001/07/24 10:00
PHST- 2001/07/24 10:00 [pubmed]
PHST- 2001/08/10 10:01 [medline]
PHST- 2001/07/24 10:00 [entrez]
AID - 10.1002/1097-0142(20010715)92:2<369::AID-CNCR1332>3.0.CO;2-U [pii]
AID - 10.1002/1097-0142(20010715)92:2<369::aid-cncr1332>3.0.co;2-u [doi]
PST - ppublish
SO  - Cancer. 2001 Jul 15;92(2):369-76. doi: 
      10.1002/1097-0142(20010715)92:2<369::aid-cncr1332>3.0.co;2-u.